ECM
ENTA icon

Endurant Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Endurant Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-131,100
Closed -$4.01M – 99
2015
Q1 		$4.01M Buy
+131,100
New +$5.1M 1.33% 24

Other funds holding ENTA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
MVM
McClain Value Management New Canaan, Connecticut $50.9M AUM 16.06% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Endurant Capital Management's ENTA Position: Q2 2015 in Review

Endurant Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2015, closing a stake of 131,100 shares — an estimated $4.01M sold.

Endurant Capital Management first reported a position in ENTA in Q1 2015 and held it in 1 quarter. The position peaked at $4.01M in Q1 2015. 131 funds tracked by Wall St. Rank hold ENTA as of Q2 2015.

  • Endurant Capital Management reported no remaining Enanta Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Endurant Capital Management sold 131,100 Enanta Pharmaceuticals shares in Q2 2015, an estimated $4.01M.
  • Endurant Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Endurant Capital Management's Enanta Pharmaceuticals position peaked at $4.01M in Q1 2015.
  • 131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2015.

Based on Endurant Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.